Scisparc Ltd
NASDAQ:SPRC
Scisparc Ltd
Research & Development
Scisparc Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Scisparc Ltd
NASDAQ:SPRC
|
Research & Development
-$1.7m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-13%
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Research & Development
-$12.8m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Research & Development
-$9.6m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Research & Development
-$67.7m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Research & Development
-$5.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
M
|
Matricelf Ltd
TASE:MTLF
|
Research & Development
-₪10.7m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Scisparc Ltd
Glance View
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The firm is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
See Also
What is Scisparc Ltd's Research & Development?
Research & Development
-1.7m
USD
Based on the financial report for Dec 31, 2024, Scisparc Ltd's Research & Development amounts to -1.7m USD.
What is Scisparc Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-13%
Over the last year, the Research & Development growth was -4%. The average annual Research & Development growth rates for Scisparc Ltd have been 5% over the past three years , -1% over the past five years , and -13% over the past ten years .
